---

$0.95

-0.0280 ( -2.86% ) 291.2K

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-14	Sale	-47500.00	BAKER BROS. ADVISORS LP
2024-05-03	Sale	-380000.00	Louis Chrystal
2024-04-23	Buy	825968.00	BAKER BROS. ADVISORS LP
2024-04-23	Buy	5000000.00	Lynx1 Capital Management LP
2024-02-02	Sale	-750000.00	Amello Jason
2023-12-21	Buy	28830.00	BARBERICH TIMOTHY J
2023-12-18	Buy	5000.00	Klencke Barbara
2023-12-08	Sale	-17500.00	Woods Keith